2026-525215-13-00招募中1 期
A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 49
- 试验地点
- 30
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (30)
Loading locations...
相似试验
招募中
1 期
A Phase I Study of RO7589831 Alone and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors2023-503170-20-01F. Hoffmann-La Roche AG46
招募中
1 期
A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease2025-524693-42-00F. Hoffmann-La Roche AG196
招募中
1 期
A study investigating the safety of RO7795081 and the effect of RO7795081 on how the body processes different approved medications. RO7795081 is a new compound that may potentially be used in the treatment of type 2 diabetes and weight control2024-519277-18-00F. Hoffmann-La Roche AG40
招募中
1 期
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effect of RO7795074 on how the body processes pitavastatin2025-521921-34-00Genentech Inc.32
招募中
1 期
A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants with Type 2 Diabetes Mellitus(T2DM) and Overweight or Obesity2025-521401-41-00F. Hoffmann-La Roche AG30